CHANNEL THERAPEUTICS CORP (CHRO)
US1711261057 - Common Stock
Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model
FREEHOLD, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), a pioneer in the...
Friday's after hours session: top gainers and losers
After hours stock analysis on 2024-12-06: top gainers and losers in today's session.
Chromocell Announces Name Change to “Channel Therapeutics Corporation” and Provides Therapeutic Program Updates
“Channel Therapeutics” reflects the Company’s focus on developing therapeutics to treat pain utilizing sodium channel blockade and modulationNew name is in...
Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain
FREEHOLD, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer...
Chromocell to Present at Upcoming Fall Investor Conferences
FREEHOLD, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer...
Chromocell Announces Amendment to Stock Repurchase Plan
FREEHOLD, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer...
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
CHRO Stock Earnings: Chromocell Therapeutics Reported Results for Q2 2024
Chromocell Therapeutics just reported results for the second quarter of 2024.
Chromocell Announces Stock Repurchase Plan
FREEHOLD, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer...
Chromocell to Participate in the Virtual Investor Lunch Break Series
Live webcast with Frank Knuettel II, Chief Executive Officer and Chief Financial Officer, on Thursday, July 18th at 12:00 PM ET...
CHRO Stock Earnings: Chromocell Therapeutics Reported Results for Q1 2024
Chromocell Therapeutics just reported results for the first quarter of 2024.
Chromocell To Present at Alliance Global Partner’s Healthcare Company Showcase on Tuesday, May 21, 2024
FREEHOLD, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to dive into the biggest pre-market stock movers with all of the hottest news worth reading about on Wednesday!
Chromocell Issues Letter to Stockholders from Chief Executive Officer
FREEHOLD, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer...
Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler
New Program Targets Estimated $2.5 Billion Eye Pain Market...
Chromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023
FREEHOLD, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in...
Chromocell to Present at Sidoti Virtual Investor Conference March 13-14
AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the...
Benuvia Operations, LLC and Chromocell Therapeutics Corp. Announce Strategic Partnership to Advance Healthcare Solutions
AUSTIN. Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Benuvia Operations, LLC (“Benuvia”), a leader in pharmaceutical innovation, and Chromocell Therapeutics...
Chromocell Therapeutics Announces Closing of Initial Public Offering for Gross Proceeds of $6.6 Million
FREEHOLD, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (NYSE American: CHRO) (“Chromocell”, “our”, “us” or the “Company”),...
Chromocell stock down 11% following $7M IPO (Pending:CHRO)
Chromocell (CHRO) stock was trading 11% lower Friday following the pain medication developer's $7M IPO. Read more here.
Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering
FREEHOLD, N.J., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (NYSE American: CHRO) (“Chromocell” or the “Company”), a...
Table of specialists: The future of work after the pandemic
CHRON Announces Engagement with Coit Capital, a FINRA Registered Broker-Dealer to Secure Steady & Scalable Financing for its Zero Cost Program(TM) Commercial Contracts
Zen Technologies Completes Initial "Zero-Cost" Commercial Customer Installation -- Successful Testing of Zen's Systems, Infrastructure, Logistics, and Technicians